NEW YORK , July 26, 2024 /PRNewswire/ -- The global motion sickness drugs market size is estimated to grow by USD 139.5 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 4.
37% during the forecast period. availability of over-the-counter (OTC) drugs is driving market growth, with a trend towards advent of nauseogenic information technology. However, nonpharmacological countermeasures to treat motion sickness poses a challenge.
Key market players include Abbott Laboratories, Amneal Pharmaceuticals Inc., Baxter International Inc., CVS Health Corp.
, DM Pharma Marketing Pvt. Ltd., GlaxoSmithKline Plc, Hylands, Lupin Ltd.
, Merck KGaA, Myungmoon Pharm Co. Ltd., Novartis AG, Perrigo Co.
Plc, Prestige Consumer Healthcare Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
, Tivic Health Systems Inc., Viatris Inc., WellSpring Pharmaceutical Corp.
, Zenomed Healthcare Pvt. Ltd., and Zydus Lifesciences Ltd.
. Get a detailed analysis on regions, market segments, customer landscape, and companies - Click for the snapshot of this report Key Market Trends Fueling Growth Motion sickness is a common issue that restricts individuals from traveling comfortably. Current treatments for motion sickness are unsatisfactory, but recent advancements in brain imaging, neuron physiology, and neuropharmacology offer potential solutions.
Neurophysiology, pathway mapping, and MRI techniques have been employed to study the brain's cortex, cere.